Your Location：
Home >
Browse articles >
CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?
LETTER TO THE EDITOR | Updated：2023-02-28
Previous|Next

    • CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?

    • Zi-Qing Li , Chao-Hong Li
    • Military Medical Research Vol. 8, Issue 3, Pages: 450-452(2021)

    • DOI： 10.1186/s40779-020-00292-2     

      CLC：

    Scan QR Code

  •  
  •  

  • Full Text(HTML)

  • References

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

13

Views

12

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges
Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research
Applications of CRISPR-Cas9 mediated genome engineering
Engineered exosomes for diabetic foot ulcers: lessons learned, challenges remain
Frostbite: diagnosis, treatment, prognosis, and future directions

Related Author

Mohammed Fatih Rasul
Mohammad Taheri
Wojciech Branicki
Mark C. Glassy
Milladur Rahman
Soudeh Ghafouri-Fard
Aria Baniahmad
Abbas Salihi

Related Institution

Department of Medical Laboratory Science, Komar University of Science and Technology
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences
Faculty of Biology, Institute of Zoology and Biomedical Research, Jagiellonian University
Translational Neuro-Oncology Laboratory, San Diego (UCSD) Moores Cancer Center, University of California
Department of Clinical Sciences, Malmö, Section for Surgery, Lund University